文献速递血液净化与透析

血液透析起始时继续使用袢利尿剂与临床结局的关联

Association of Continuation of Loop Diuretics at Hemodialysis Initiation with Clinical Outcomes.
PubMed 文献 · Clin J Am Soc Nephrol · 2018-12-19

本研究纳入11,297例在透析起始时已有袢利尿剂活跃处方的中心血液透析患者,评估继续使用袢利尿剂与透析第一年临床结局的关联。调整混杂因素后,继续使用袢利尿剂与较低的住院率和透析中低血压发生率相关,且透析间期体重增长较低,但死亡率无差异。

要点

  • 透析起始后继续使用袢利尿剂与住院率降低相关(aIRR 0.93)。
  • 继续使用袢利尿剂与透析中低血压发生率降低相关(aIRR 0.95)。
  • 继续使用袢利尿剂与透析间期体重增长较低相关(P=0.03),死亡率无差异。

核心结论

  • 血液透析起始后继续使用袢利尿剂与较低的住院率和透析中低血压发生率相关,且透析间期体重增长较低,但第一年死亡率无差异。

研究设计与样本

  • 回顾性队列研究,纳入2006-2013年某大型透析组织中11,297例在透析起始时已有袢利尿剂活跃处方的中心血液透析患者,按意向治疗原则随访至12个月。

主要发现

  • 继续使用袢利尿剂组5,219例,对照组6,078例。
  • 调整后住院率aIRR 0.93(95%CI 0.89-0.98),透析中低血压aIRR 0.95(95%CI 0.92-0.99)。
  • 死亡率aHR 0.92(95%CI 0.84-1.01),透析间期体重增长较低(P=0.03)。

临床怎么用

  • 对于透析起始前已使用袢利尿剂的患者,继续使用可能减少住院和透析中低血压,并有助于控制透析间期体重增长。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Loop diuretics are commonly used to manage nondialysis-dependent CKD. Despite benefits of augmented urine output, loop diuretics are often discontinued after dialysis initiation. Here, we assessed the association of the early decision to continue loop diuretics at hemodialysis start with clinical outcomes during the first year of dialysis. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We considered all patients on in-center hemodialysis at a large dialysis organization (2006-2013) with Medicare Part A and D benefits who had an active supply of a loop diuretic at dialysis initiation (n=11,297). Active therapy was determined on the basis of whether loop diuretic prescription was refilled after dialysis initiation and within 30 days of exhaustion of prior supply. Patients were followed under an intention-to-treat paradigm for up to 12 months for rates of death, hospitalization, and intradialytic hypotension and mean monthly values of interdialytic weight gain, serum potassium, predialysis systolic BP, and ultrafiltration rates. RESULTS: We identified 5219 patients who refilled a loop diuretic and 6078 eligible controls who did not. After adjustments for patient mix and clinical differences, continuation of loop diuretics was associated with lower hospitalization (adjusted incidence rate ratio, 0.93; 95% confidence interval, 0.89 to 0.98) and intradialytic hypotension (adjusted incidence rate ratio, 0.95; 95% confidence interval, 0.92 to 0.99) rates, no difference in death rate (adjusted hazard ratio, 0.92; 95% confidence interval, 0.84 to 1.01), and lower interdialytic weight gain (P=0.03). CONCLUSIONS: Continuation of loop diuretics after hemodialysis initiation was associated with lower rates of hospitalization and intradialytic hypotension as well as lower interdialytic weight gain, but there was no difference in mortality over the first year of dialysis.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Sibbel S, Walker AG, Colson C, et al. Association of Continuation of Loop Diuretics at Hemodialysis Initiation with Clinical Outcomes. Clin J Am Soc Nephrol. 2018. PMID: 30567905. doi:10.2215/CJN.05080418

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。